Table 2

Subject selection (numbers of subjects are given)

Renkema7
(bud 1600 μg/bud+pred/plac)
Derenne10(becl 1500 μg/plac)Kerstjens9 (becl 800 μg/ipra/plac)
Original numberTotal: 58 (21/19/18)Total: 194 (100/94)Total: 51 (19/11/21)
Meeting inclusion criteria meta-analysis:
 Symptoms compatible with diagnosis of COPD5819451
 Age >40 years 5519239
 FEV1 post β2agonist < FEV1 pred –1.64SD4718529
 Airway reversibility ⩽ 9% pred FEV1 4317829
 (Ex-)smokers (>0 pack years)5317351
 Not meeting 1 inclusion criterion223625
 Not meeting 2 inclusion criteria668
 Not meeting 3 inclusion criteria003
 Not meeting ⩾4 inclusion criteria000
Meeting exclusion criteria meta-analysis:
 α1-Antitrypsin deficiency000
 Asthma history000
 Eligible for meta-analysis30 (6/143-150/10)152 (81/71) 15 (8/33-151/4)
  • bud = budesonide; plac = placebo; pred = prednisone; becl = beclomethasone; ipra = ipratropium.

  • 3-150 Excluded from analysis because of treatment with oral corticosteroids.

  • 3-151 Considered as “placebo” in the meta-analysis.